Therapeutic Approaches

Modalities

Comprehensive multi-modality pipeline covering small molecules, antibodies, PROTACs, and gene therapies.

Drug Modalities

Therapeutic Platforms

Diverse approaches for comprehensive cancer treatment

Small Molecules

Oral, cell-permeable inhibitors targeting intracellular oncoproteins. Fast development timeline with established manufacturing.

StagePhase 1 or pre-clinical
TargetsKRAS, EGFR, BRAF

Antibodies

Monoclonal antibodies with high target specificity for cell surface antigens and immune modulation.

StagePhase I
TargetsPD-L1, CD20, HER2

PROTACs

Targeted protein degraders eliminating disease-causing proteins through the ubiquitin-proteasome system.

StagePhase I
TargetsBCL-XL, BRD4, AR

ADCs

Antibody-drug conjugates combining targeting precision with potent cytotoxic payloads for maximum efficacy.

StagePhase 1 or pre-clinical
TargetsTROP2, HER2, Nectin-4

Gene Therapy

RNA interference and CRISPR-based approaches targeting undruggable oncogenes at the genetic level.

StagePreclinical
TargetsMYC, TP53, RAS

Bispecifics

Dual-targeting antibodies engaging both tumor cells and immune effectors for enhanced therapeutic effect.

StagePhase I
TargetsCD3xCD19, CD3xBCMA
0
Modality Platforms
0+
Active Targets
0
Clinical Candidates
0
Phase I Programs

Explore Our Therapeutic Platforms

Learn how our multi-modality approach can address your therapeutic needs.

Quantum